Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

SAP SE claimed the title of Europe’s most valuable public company, replacing Danish weight-loss drug maker Novo Nordisk A/S.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

The German software company's share price gained 40% in the past year, while Danish drugmaker Novo Nordisk has gradually lost ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...